Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brianna Albers

Podiatrist, Foot & Ankle Surgery Cincinnati, OH Doctor of Podiatric Medicine

NPI 1336705789 CMS profile 6138649

4777 E Galbraith Rd, Cincinnati, OH 45236

Open in the dashboard

General payments

$13,644

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brianna Albers of Cincinnati, OH is reported in the CMS Open Payments database as having received $13,644 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,384 19
2024 General $1,095 32
2023 General $715 22
2022 General $5,813 45
2021 General $2,884 25
2020 General $381 4
2019 General $1,373 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brianna Albers
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Brianna Albers were reported at $1,384. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Brianna Albers Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $1,373 $389 $118–$1,406 $163
2020 $381 $191 $62–$691 $114
2021 $2,884 $329 $104–$1,341 $132
2022 $5,813 $419 $125–$1,611 $149
2023 $715 $377 $128–$1,164 $160
2024 $1,095 $394 $134–$1,168 $164
2025 $1,384 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $6,230 72 payments
  2. Legacy Ortho LLC $2,400 2 payments
  3. ConvaTec Inc. $553 15 payments
  4. Smith+Nephew, Inc. $551 17 payments
  5. Bioventus LLC $527 7 payments
  6. Paratek Pharmaceuticals, Inc. $318 9 payments
  7. LifeNet Health $314 1 payment
  8. Treace Medical Concepts, Inc. $306 3 payments
  9. DePuy Synthes Sales Inc. $306 5 payments
  10. Wright Medical Technology, Inc. $257 4 payments
  11. Other $1,882 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,040 163 payments
  2. Education $2,480 4 payments
  3. Travel and Lodging $2,123 2 payments
Products named General payments · program years 2019–2025
  1. PROSTEP $2,591 7 payments
  2. ORTHOLOC 2 LAPIFUSE $547 9 payments
  3. INNOVAMATRIX AC $435 6 payments
  4. AUGMENT INJECTABLE $414 4 payments
  5. VARIAX $343 6 payments
  6. NUZYRA $318 9 payments
  7. TheraGenesis Wound Matrix $314 1 payment
  8. GRAFIX PL $291 10 payments
  9. ORTHOLOC 3DI CROSSCHECK $251 4 payments
  10. KRYSTEXXA $247 2 payments
  11. Other $5,852 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

511

Median for Podiatry: 160

Drug cost

$6,327

Median for Podiatry: $2,368

Branded share of claims

12.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 62 $1,923
Terbinafine Hcl Generic 32 $759
Ammonium Lactate Generic 36 $632
Doxycycline Hyclate Generic 42 $479
Cephalexin Generic 48 $478
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 43 $437
Mupirocin Generic 41 $306
Ketoconazole Generic 33 $292
Gabapentin Generic 39 $229
Levofloxacin Generic 26 $191

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$133,374

Of which drugs: $86

Medicare patients

556

Average age 77

Services billed

3,203

306 women, 250 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 44%
Arthritis 44%
Chronic kidney disease 38%
Ischemic heart disease 33%
Depression 26%
Atrial fibrillation 24%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 112 $86

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record